Lilotomab

Lilotomab (formerly tetulomab, HH1)[1] is a murine monoclonal antibody against CD37,[2] a glycoprotein which is expressed on the surface of mature human B cells.[3] It was generated at the Norwegian Radium Hospital.[3]

Lilotomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetCD37
Clinical data
Other namesTetulomab, HH1
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA.[2] This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin).[1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.[4]

The satetraxetan structure chelating lutetium-177[5]

References
  1. "Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector". Adis Insight. Springer Nature Switzerland AG. Retrieved 1 September 2016.
  2. "Recommended INN List 74" (PDF). WHO Drug Information. 29 (3). 2015.
  3. Robak T, Robak P (May 2014). "Anti-CD37 antibodies for chronic lymphocytic leukemia". Expert Opinion on Biological Therapy. 14 (5): 651–61. doi:10.1517/14712598.2014.890182. PMID 24555705. S2CID 19987961.
  4. "EudraCT Number: 2011-000033-36". EU Clinical Trials Registry. Treatment of lymphoma with targeted internal radiation therapy (Betalutin)
  5. "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4): 515. 2014.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.